BN Business News
Add your company to Business Communicator →

Business · 16/11/20261 min read

Akeso's Gumokimab (IL-17A) Receives NMPA Approval for Active Ankylosing Spondylitis

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

HONG KONG, Nov. 16, 2026 — Akeso, Inc. (9926.HK) announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for gumokimab, its self-developed IL-17A monoclonal antibody, for the treatment of active...

Original source language: PR Newswire — Global News ReleasesOpen original release →

Explore insights

Business insights →